Back to top
more

Masimo (MASI)

(Delayed Data from NSDQ)

$106.44 USD

106.44
1,208,547

-1.65 (-1.53%)

Updated Jul 30, 2024 04:00 PM ET

After-Market: $106.33 -0.11 (-0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (105 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Here's Why You Should Invest in Henry Schein (HSIC) Stock

Henry Schein's (HSIC) strategy to extend digital dentistry globally is encouraging. Recent acquisitions will strengthen its foothold in the high-potential dental market.

    Varian (VAR) & Reliance Group Tie Up to Enhance Cancer Care

    Varian (VAR) enjoys solid presence in Asia, Latin America and Africa's cancer care space.

      Here's Why You Should Hold Medidata Stock in Your Portfolio

      Medidata's (MDSO) Clinical Cloud platform is likely to provide it a competitive edge in the MedTech space. However, cutthroat competition in the niche space is a headwind.

        Will Walgreens (WBA) Q4 Earnings Gain From Overall Strength?

        Several planned developments, early benefits of new pharmacy contracts as well as an increase in volume are consistently driving growth within Walgreens Boots' (WBA) Retail Pharmacy USA division.

          Europe Okays Use of Insulet's (PODD) Omnipod With Fiasp

          Fiasp's operative efficiency coupled with Insulet's (PODD) Omnipod System will provide a new option for both patients and prescribers to support their diabetes management requirements.

            Genomic Health's New Data on Oncotype DX GPS to Boost Uptake

            Genomic Health (GHDX) continues to see positive developments within the U.S. prostate cancer test business.

              Thermo Fisher (TMO) Scales a 52-Week High: What's Driving It?

              Thermo Fisher (TMO) sees strength in all end markets, categorized either by customer type or geography.

                Here's Why You Should Hold Integer Holdings in Your Portfolio

                Integer Holdings' (ITGR) new strategy to drive sales and profit growth to provide the company with a competitive edge in the MedTech space.

                  Merit Medical (MMSI) to Acquire Cianna Medical, Shares Up

                  Merit Medical (MMSI) to leverage on Cianna Medical's SAVI and SCOUT platforms. The company plans to retain Cianna Medical's commercial and R&D teams after closure of the transaction.

                    Boston Scientific Grows on Acquisitions, Product Launches

                    Boston Scientific's (BSX) strategy to extend its existing portfolio through inorganic growth profile has been advancing well. Further, this should help aid the company's top line in the long term.

                      Abbott's CE Mark for FreeStyle Libre 2 Boosts Diabetes Arm

                      Abbott (ABT) focuses on boosting diabetes care. The latest CE Mark will increase the top-line contributions from the Diabetes unit.

                        Here's Why You Should Invest in CVS Health (CVS) Stock Now

                        CVS Health's (CVS) solid cash position is encouraging. Strong 2019 PBM selling season is another upside.

                          Here's Why You Should Buy Inogen (INGN) Stock Right Now

                          Inogen (INGN) is expected to gain from strong international foothold and a raised view for 2018.

                            Baxter Collaborates With Mayo Clinic to Open Renal Care Center

                            Per the agreement, Baxter (BAX) and Mayo Clinic researchers to form an outpatient clinic for kidney disease management, home dialysis and in-center dialysis services.

                              Henry Schein's 3 Investments to Fortify Dental Implant Arm

                              Intra-Lock, Medentis Medical and Pro-Cam Implants jointly are likely to prove conducive to growth for Henry Schein's (HSIC) existing implant-based tooth replacement solutions line.

                                AngioDynamics (ANGO) Q1 Earnings Miss, '19 Sales View Up

                                AngioDynamics (ANGO) sees soft segmental performances in Q1; international sales surge.

                                  Quest Diagnostics Plans a Buyout to Widen TB Testing Suite

                                  Quest Diagnostics (DGX) progresses well with regard to its strategy to grow inorganically.

                                    STERIS (STE) Strategic Growth Strong Amid Several Headwinds

                                    STERIS (STE) impresses with favorable underlying market trends apart from new products and service offerings. Yet, a severe competition lurking beneath is worrisome for the company.

                                      Quest Diagnostics Inks Lab Service Deal With ReproSource

                                      Per agreement with ReproSource, Quest Diagnostics (DGX) to perform laboratory reference testing besides providing supply chain expertise.

                                        Abbott's Troponin-I Wins CE Mark, Vascular Arm Gets a Revamp

                                        Abbott's (ABT) life-changing High Sensitive Troponin-I test uses a biomarker, specific to the heart.

                                          Cerner CommunityWorks Selected by Pershing Health System

                                          Cerner (CERN) witnesses consistent growth in the Electronic Health Record platform and Revenue Cycle Management solutions.

                                            Hologic's Focal Therapeutics Buyout to Boost Breast Health Arm

                                            Hologic (HOLX) progresses with initiatives to boost the Breast Health unit. The recent buyout is likely to widen portfolio and fortify Hologic's position in the breast conserving surgery market.

                                              Here's Why You Should Add Edwards Lifesciences Right Away

                                              We are upbeat about the continued strength in Edwards Lifesciences' (EW) THVT business.

                                                Baxter's (BAX) ALTAPORE Bioactive Bone Graft Gets FDA Nod

                                                Baxter's (BAX) offers a broad spectrum of surgical products, including bone grafts and substitutes that see lucrative market prospects.

                                                  Will LabCorp's (LH) Food Solution Divestment Upset Sales?

                                                  LabCorp's (LH) lackluster outlook for 2018 includes the earlier-announced divestment of its Food Solutions business.